KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Other Gross PP&E Adjustments (2016 - 2026)

Emergent BioSolutions has reported Other Gross PP&E Adjustments over the past 16 years, most recently at $499.5 million for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments fell 2.29% year-over-year to $499.5 million; the TTM value through Mar 2026 reached $499.5 million, down 2.29%, while the annual FY2025 figure was $498.9 million, 23.95% down from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 was $499.5 million at Emergent BioSolutions, roughly flat from $498.9 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $1.2 billion in Q4 2022 and troughed at $493.3 million in Q3 2025.
  • A 5-year average of $781.6 million and a median of $771.2 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: rose 18.8% in 2022 and later tumbled 35.02% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at $1.2 billion in 2022, then plummeted by 34.18% to $778.0 million in 2023, then fell by 15.68% to $656.0 million in 2024, then dropped by 23.95% to $498.9 million in 2025, then grew by 0.12% to $499.5 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for EBS at $499.5 million in Q1 2026, $498.9 million in Q4 2025, and $493.3 million in Q3 2025.